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Abstract
Purpose To determine the small intestinal concentration of endocannabinoids (ECs), N-acylethanolamines (NAEs) and their 
precursors N-acylphosphatidylethanolamines (NAPEs) in humans. To identify relationships between those concentrations 
and habitual diet composition as well as individual inflammatory status.
Methods An observational study was performed involving 35 participants with an ileostomy (18W/17M, aged 18–70 years, 
BMI 17–40 kg/m2). Overnight fasting samples of ileal fluid and plasma were collected and ECs, NAEs and NAPEs concen-
trations were determined by LC-HRMS. Dietary data were estimated from self-reported 4-day food diaries.
Results Regarding ECs, N-arachidonoylethanolamide (AEA) was not detected in ileal fluids while 2-arachidonoylglycerol 
(2-AG) was identified in samples from two participants with a maximum concentration of 129.3 µg/mL. In contrast, mean 
plasma concentration of AEA was 2.1 ± 0.06 ng/mL and 2-AG was 4.9 ± 1.05 ng/mL. NAEs concentrations were in the range 
0.72–17.6 µg/mL in ileal fluids and 0.014–0.039 µg/mL in plasma. NAPEs concentrations were in the range 0.3–71.5 µg/
mL in ileal fluids and 0.19–1.24 µg/mL in plasma being more abundant in participants with obesity than normal weight and 
overweight. Significant correlations between the concentrations of AEA, OEA and LEA in biological fluids with habitual 
energy or fat intakes were identified. Plasma PEA positively correlated with serum C-reactive protein.
Conclusion We quantified ECs, NAEs and NAPEs in the intestinal lumen. Fat and energy intake may influence plasma and 
intestinal concentrations of these compounds. The luminal concentrations reported would allow modulation of the homeo-
static control of food intake via activation of GPR119 receptors located on the gastro-intestinal mucosa.
Clinical trial registry number and website NCT04143139; www.clini caltr ials.gov.
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GLP-1  Glucagon-like peptide 1
GPCRs  G-protein-coupled receptors
LA  Linoleic acid
LC-HRMS  Liquid chromatography–high-resolution 
mass spectrometry
LEA  Linoleoylethanolamide
MUFA  Monounsaturated fatty acids
NAAA  N-Acylethanolamine-hydrolyzing acid 
amidase
NAEs  N-Acylethanolamines
NAPE-PLD  N-Acyl-phosphatidylethanolamine-specific 
phospholipase D
NAPEs  N-Acylphosphatidylethanolamines
OEA  Oleoylethanolamide
PEA  Palmitoylethanolamide
PAEE  Physical activity energy expenditure
PPAR-α  Peroxisome proliferator-activated receptor
PUFA  Polyunsaturated fatty acids
RPAQ  Recent physical activity questionnaire
SFA  Saturated fatty acids
Introduction
Endocannabinoids (ECs) and their structural congeners 
N-acylethanolamines (NAEs), also known as “endocan-
nabinoid-like molecules”, are endogenous lipid mediators 
involved in a wide range of biological pathways regulating 
appetite, nutrient metabolism, energy balance and inflam-
mation [1, 2]. ECs include 2-arachidonoylglycerol (2-AG) 
and N-arachidonoylethanolamide (AEA) [3] while the most 
studied NAEs are N-oleoylethanolamide (OEA), N-palmi-
toylethanolamide (PEA), N-linoleoylethanolamide (LEA) 
and N-stearoylethanolamide (SEA) [4, 5].
Circulating NAEs and AEA as well as 2-AG are formed 
from membrane precursors, such as N-acylphosphatidyleth-
anolamines (NAPEs) and diacylglycerol, through the activ-
ity of NAPE-specific phospholipase D (NAPE-PLD) and 
diacylglycerol lipase (DAGL), respectively. Other enzymes 
hydrolyse NAEs and ECs to fatty acids and ethanolamines 
[6–8].
ECs elicit their biological activities through the can-
nabinoid type 1 (CB1) and type 2 (CB2) receptors which 
are located mainly in the brain but also in peripheral tis-
sues, such as the intestine, liver, skeletal muscle, vascular 
endothelium, reproductive tissues, and tissues of the immune 
system [5]. NAEs regulate food intake, glucose homeosta-
sis and inflammation through activation of G protein-cou-
pled receptors (GPCRs), peroxisome proliferator-activated 
receptors (PPAR-α), and transient receptor vanilloid poten-
tial receptors (TRVP) [9–11]. Some of these receptors are 
located on cells lining in the gastro-intestinal tract (GIT). 
For example, GPR119 is expressed on cells in the stomach, 
small intestine and colon [12] and, upon NAE-mediated 
activation, it elicits the secretion of the insulin-regulating 
peptides, glucagon-like peptide 1 (GLP-1) and glucose-
dependent insulinotropic peptide (GIP) [13, 14]. PPAR-α 
is expressed in the small intestine, kidneys, liver, heart and 
brown adipose tissue and increases satiety through its ligand 
OEA [15–17]. In contrast, 2-AG and AEA stimulate food 
intake through the CB1 receptors [18].
Mounting evidence in subjects with inflammatory bowel 
disease and obesity indicates that circulating ECs are key 
mediators in the interplay between gut, microbiota and meta-
bolic health [19–23]. Moreover, plasma ECs and NAEs are 
considered biomarkers of white adipose tissue distribution 
and insulin resistance in obesity [24–32] and, as NAPEs, 
they are tightly connected with diet, especially dietary fat 
[1] but also proteins [33, 34].
On the other hand, ECs, NAEs, and NAPEs are present 
in several foods [35], they increased in saliva upon food 
mastication in humans [36, 37] and the direct injections of 
NAPEs in the duodenum reduced food intake in mice [38]. 
Altogether, this evidence raised the question of whether the 
luminal content of ECs, NAEs, and NAPEs may be sufficient 
to elicit biological effects through the receptors located in 
the GIT.
Therefore, we determined the concentrations of ECs, 
NAEs and NAPEs in ileal fluids and plasma collected dur-
ing an observational study in participants with ileostomy and 
investigated their relationship with habitual macronutrient 
and energy intake as well as with individual inflammatory 
status.
Methods
Study design
This study is part of an observational study (16/NI/0267) 
whose primary outcome was the assessment of bone min-
eral density (by Dual-energy X-ray absorptiometry) in 
ileostomy patients. Secondary outcomes included: anthro-
pometric measurements, habitual diet, blood lipid profile, 
blood inflammatory marker, blood polyunsaturated fatty 
acids, blood and ileal endocannabinoids, and physical activ-
ity. The study was conducted with the prior approval of the 
Office for Research Ethics Committees Northern Ireland 
(ORECNI), the University of Ulster Ethical Committee and 
with the informed consent of participants and in accordance 
with the Declaration of Helsinki. The trial was registered at 
www.clini caltr ials.gov (NCT04143139). Participants (male 
and non-pregnant females) recruited to the study were aged 
18–70 years and had previously undergone an ileostomy 
and were 2 + years post-operative at time of recruitment. 
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Participants were excluded if they were outside the desired 
age range or had their surgical procedure < 2 years before.
Following an overnight fast, the participants visited the 
clinic of Ulster University in Coleraine (UK) and provided 
ileal fluid sample and blood samples.
All participants provided questionnaires including a 4-day 
estimated food diary to establish habitual dietary intake com-
pleted within ± 14 days of sampling, subsequently analysed 
using Nutritics Nutrition Analysis Software. A validated 
Recent Physical Activity Questionnaire (RPAQ) [39] was 
also completed by each participant to capture self-reported 
habitual activity levels at home, work and in leisure time. 
The total physical activity energy expenditure (PAEE) was 
estimated by summing up the individual energy expenditure 
due to each activity domain (home, work and recreational).
Preparation of biological samples
To avoid handling bias with ileal fluids, we used method-
ologies consistent with precautions as described in Karu 
et al. [40] for metabolomic analysis in faeces. The ileal fluid 
samples were collected and processed within 30 min as 
described in Mc Dougall et al. [41]. In brief, volumes and 
pH values of the ileal fluids were recorded, before dilution 
with ice-cold distilled water as required, dependent on the 
viscosity, and before the fluid was homogenized in a chilled 
Waring blender for 30 s.
Fasting blood samples were collected by venipuncture 
into serum separator and EDTA-containing tubes. To avoid 
EDTA blood samples handling bias that may lead to ex vivo 
biotransformation of monitored compounds, we used recom-
mendations of Gurke and co-workers [42]. All EDTA blood 
samples were kept chilled/on ice before processing. Plasma 
samples were prepared by centrifugation at 3000 rpm for 
15 min at 4 °C and within 15 min of collection. Serum sam-
ples were prepared by allowing blood to clot for 30 min 
at room temperature, then centrifugation at 3000 rpm for 
15 min at 4 °C.
Once prepared, ileal fluids, serum and plasma samples 
were aliquoted and immediately frozen at − 80 °C. All 
samples were kept frozen at Ulster University according to 
Human Tissue Act (HTA) standards until further analysis.
Extraction of ECs, NAEs and NAPEs from ileal 
and plasma samples
Simultaneous extractions of ECs, NAEs and NAPEs from 
ileal fluids and plasma were performed using the method by 
Bligh and Dyer with brief modifications [43]. All samples 
were thawed in the fridge at 4 °C before extraction and sam-
ples were kept chilled on ice during the specific extraction 
procedures [42]. The ileal fluids samples were diluted prior 
the extraction to enhance the efficiency of solvent extraction 
as previously reported in faeces [40, 44].
Ileal fluids (100 µL) previously diluted 1:10 with distilled 
water and plasma samples (500 µL) were added to 50 µL of 
the internal standard 200 ng/mL solution of Arachidonoyle-
thanolamide d8 (AEA d8) (Cayman Chemical, Ann Arbor, 
MI). A volume of 1.5 mL of  CHCl3/CH3OH (2:1 v/v) was 
added to the sample that was vortexed for 20 s and centri-
fuged at 14,800 rpm for 10 min at 4 °C. Then, the superna-
tant was collected in a glass tube and the pellet was extracted 
with  CHCl3/CH3OH (2:1) twice. KCl 0.07 M (2 mL) was 
added to the collected phase and the lower layer (chloroform 
phase) was evaporated under nitrogen flow and reconstituted 
in 100 µL acetonitrile/isopropanol/water (60:35:5) prior the 
LC-HRMS analysis.
The extraction recovery was 86% in ileal fluids and 71% 
in plasma samples.
Liquid chromatography–high‑resolution mass 
spectrometry (LC‑HRMS) analysis
LC-HRMS analysis was performed by adapting the method 
by Gregory et al. [44]. Data were collected using an Accela 
U-HPLC system consisting of a quaternary pump and a 
thermostated autosampler (10 °C) coupled to an Exactive 
Orbitrap MS provided with a heated electrospray interface 
(HESI) (Thermo Fisher Scientific, San Jose, CA). The com-
pounds were separated on a Kinetex 2.6 μ C18 100 Å col-
umn (100 mm × 2.1 mm) (Phenomenex, Torrance, CA) with 
setting temperature at 45 °C and eluted by a linear gradient 
of a 40:60 water/acetonitrile mixture (5 mM ammonium for-
mate 0.1% formic acid) (solvent A) and 90:10 isopropanol/
acetonitrile (5 mM ammonium formate and 0.1% formic 
acid) (solvent B) with a flow rate of 200 μL/min and volume 
injection of 10 μL. According to Gregory et al., eluting gra-
dient was set as follows: 32% B from 0 to 1.5 min, 32–45% 
B from 1.5 to 4 min, 45–52% B from 4 to 5 min, 52–58% 
B from 5 to 8 min, 58–66% B from 8 to 11 min, 66–70% B 
from 11 to 14 min, 70–75% B from 14 to 18 min, 75–97% B 
from 18 to 21 min and kept at 97% B until 25 min [44]. MS 
detection was performed in positive- and negative-ion modes 
in the m/z 120–1200 mass range: spray voltage was 3.5 kV 
(positive mode) and 3.0 kV (negative mode), capillary volt-
age 30 V, heater temperature 300 °C, capillary temperature 
at 350 °C, sheath gas 35 and auxiliary gas 15 arbitrary units, 
respectively.
Compounds were identified and quantified against authen-
tic standards using exact mass value up to the fifth decimal 
digit (± 5 ppm mass tolerance). ECs (2-AG; AEA; AEAd8) 
and NAEs (OEA, LEA, PEA) standards were purchased 
from Cayman (Cayman Chemical, Ann Arbor, MI). N-ara-
chidonoylphosphatidylethanolamine standard was purchased 
from Santa Cruz Biotechnology (Santa Cruz Biotechnology, 
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Inc., USA). SEA was expressed as equivalents of PEA. 
NAPEs were found in the chromatographic region between 
19 and 23 min and were detected in negative-ion mode as 
[M − H]−. In the chromatographic region between 6 and 
9 min, the NAEs were detected in positive-ion mode as 
[M + H]+. Supplementary Table 1 reports the molecular for-
mula, theoretical and experimental mass, the mass accuracy 
and the retention time of identified compounds. The limit 
of detection (LoD) and limit of quantification (LoQ) of the 
identified molecules are reported in Supplementary Table 2.
Biochemical analysis
Circulating lipid profiles (serum triglycerides, total and 
HDL cholesterol) were quantified on the iLab 650 Clinical 
Chemistry auto-analyzer (Instrumentation Laboratory, Mas-
sachusetts, USA) using a commercially available assay. LDL 
cholesterol was calculated using the Friedewald formula 
[45]. Serum C-reactive protein (CRP) was measured at the 
clinical chemistry department of St James’ Hospital Dublin.
Total lipid was extracted from serum according to a 
modified version of Folch et  al. [46] where chloroform 
and methanol were used as the extracting solvents in 
a 2:1 ratio, with 250 µL of plasma extracted in 5 mL of 
extracting solvents [47], the wash solution was 3:47:48 
(chloroform:methanol:water). Fatty acid methyl esters 
were detected and quantified for six key polyunsaturated 
fatty acids (PUFA)—linoleic acid (LA), arachidonic acid 
(AA), α-linolenic acid (ALA), eicosapentaenoic acid (EPA), 
docosapentaenoic acid (DPA) and docosahexaenoic acid 
(DHA) using the gold-standard technique of gas chroma-
tography–mass spectrometry (7890A-5975C; Agilent) using 
heptadecanoic acid (C17:0) as the internal standard, as pre-
viously described [47]. In brief, to a 250 µL plasma sample, 
18 µL internal standard (heptadecanoic acid (C17:0)) was 
added and then chloroform:methanol (2:1) to a final volume 
of 5 mL. The solution was vigorously mixed, 1 mL  DDH2O 
added, then centrifuged at 2500g for 5 min. The upper layer 
was discarded, the remaining solution washed twice with 
chloroform:methanol:water (3:48:47) and the sample fil-
tered, then evaporated to dryness (at 70 °C, under nitrogen). 
Toluene (100 µL) and borontrifluoride methanol (500 µL) 
were added and the solution maintained at 100 °C for 1 h. 
Subsequently, 250 µL of hexane and 800 µL  DDH2O were 
added to the cooled sample and mixed. The supernatant was 
then removed and evaporated to dryness (at 50 °C, under 
nitrogen). Extractions were reconstituted in 180 µL ethyl 
acetate before analysis on GC/MS which was completed in 
split mode (split ratio 1:20), with a BPX70 capillary GC 
column (SGE Analytical Science) (length 30 m, internal 
diameter 250 µm and film thickness 0.25 µm), using helium 
as the carrier gas (constant flow at 1.0 mL/min). Samples 
were injected using an automatic liquid sampler (ALS) 
(injection volume 1 µL) at a temperature of 130 °C, this was 
then ramped at 15 °C/min to 200 °C and then at 30 °C/min to 
250 °C where it was held for 5 min. Mass Spectrometry was 
operated in positive-ion mode using an electron ionisation 
(EI) source. The mass range was set to 50–500 Da and acqui-
sition was performed by Total Ion Chromatogram (TIC). 
We identified the individual PUFA—LA, AA, ALA, EPA, 
DPA and DHA—by their retention time and corresponding 
qualifier ions with reference to those of commercially avail-
able fatty acid standards (Sigma Aldrich, UK). These were 
quantified by use of an internal standard, heptadecanoic acid 
(C17:0) (Sigma Aldrich, UK) and corresponding PUFA tar-
get ions (quantifiers). For the purpose of this paper, we have 
defined: Total PUFA as the sum of LA, ALA, AA, EPA, 
DPA, DHA; n-3 fatty acids as the sum of ALA, EPA, DPA 
and DHA; n-6 fatty acids as the sum of LA and AA; n-6:n-3 
ratio as the ratio between n-6 and n-3 fatty acids.
Anthropometric measurements
Height and weight were measured using standardized proce-
dures to determine Body Mass Index (BMI, kg/m2). Stand-
ing height (cm) was measured to the nearest 0.5 cm using a 
calibrated stadiometer (SECA, Model 220, Germany). Body 
weight (kg) was recorded without footwear or heavy clothing 
and was measured to the nearest 0.1 kg using portable scales 
(Seca; Brosch Direct Ltd, Peterborough, UK). Participants 
were considered with normal weight when the BMI was in 
the range 18.5–24.9 kg/m2, with overweight when the BMI 
was in the range 25.0–29.9 kg/m2 and with obesity when the 
BMI was higher than 30 kg/m2.
Statistical analysis
Statistical analyses were performed in R version 3.6.0. After 
being checked for normality, significantly skewed variables 
were transformed in ln (x) with k values. For those that 
showed a normal distribution at the Kolmogorov–Smirnov 
test, Student’s t test was performed to check differences 
between sexes. One-way ANOVA and Bonferroni adjust-
ment for multiple comparisons were performed to check dif-
ferences between compounds in the overall population. For 
the variables which did not show a normal distribution after 
logarithmic transformation, a non-parametric Mann–Whit-
ney test was performed. Two-tailed P values lower than 0.05 
were considered significantly different. To test correlations 
between concentrations of NAPEs, NAEs and ECs in bio-
logical fluids with the dietary intake, all variables were 
transformed in ln(x) and a Pearson correlation test was per-
formed to check the best model to fit the curve. In all cases, 
logarithmic model was selected and results obtained were 
reported. Data are expressed as means ± SEM.
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Results
Study participants
The participant flow is shown in Fig. 1. 35 participants with 
ileostomy were recruited and completed the study. The char-
acteristics of the participants including general information 
and anthropometry, serum lipids, PUFA and CRP as well as 
the mean dosages of each type of medication taken by 27 
subjects, are reported in Table 1. Differences between sexes 
were found for height and weight that were higher, as well 
as serum HDL-cholesterol concentrations that were lower, 
in men than women. The participants had a mean BMI of 
26.9 ± 0.9 kg/m2, specifically there was 1 subject (1 man) 
who was underweight, 11 subjects (8 women and 3 men) 
with normal weight (NW), 12 (7 women and 5 men) with 
overweight (OW) and 11 (3 women and 8 men) with obesity 
(OB). Compared to NW, OB showed higher triglycerides 
(1.19 ± 0.15 mmol/L vs 0.6 ± 0.06 mmol/L, p = 0.002) and 
lower HDL-cholesterol concentrations (0.99 ± 0.08 mmol/L 
vs 1.32 ± 0.06 mmol/L, p = 0.013). No significant difference 
between BMI classes for general characteristics and CRP 
was observed.
Concentration of ECs, NAEs and NAPEs in ileal fluids
Figure 2 shows the ileal concentrations of monitored NAEs 
and NAPEs in overall population and some significant dif-
ferences between sexes and BMI classes.
Mean concentrations of NAEs and NAPEs were 
not significantly different (3346.94 ± 561.39  ng/mL vs 
4896.99 ± 2043.01 ng/mL).
LEA was the most abundant NAE and it was, like OEA, 
significantly higher in men than women while PEA concen-
tration was significantly higher in OW than NW.
No differences between sexes in ileal concentrations of 
PEA, SEA and NAPEs or between BMI classes in ileal LEA, 
OEA, SEA and NAPEs concentrations were found (Sup-
plementary Fig. 1).
Plasma concentration of ECs, NAEs and NAPEs
Figure 3 shows the plasma concentrations of all monitored 
compounds in the population. In contrast to ileal fluids, AEA 
and 2-AG were frequently detected and in similar concentra-
tions in plasma. PEA was the most abundant NAE followed 
by SEA, and similar concentration of OEA and LEA.
Fig. 1  Participants flow
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No difference in plasma NAEs between sexes and 
between BMI classes was observed (Supplementary Fig. 2). 
Contrarily, circulating levels of plasma NAPEs were higher 
in OB compared to NW subjects (Fig. 3).
Interestingly, positive logarithmic correlations between 
plasma CRP with PEA (r = 0.411, p = 0.014) and BMI 
(r = 0.363, p = 0.032) were found (Fig.  4). Although, 
subjects who took supplements had lower serum CRP 
concentrations than those who did not (2.66 ± 0.95 and 
3.83 ± 0.92, p = 0.024) (Supplementary Fig. 3), supple-
ment consumption did not affect plasma ECs, NAEs and 
NAPEs concentration.
No significant association between plasma concentra-
tion of the monitored compounds and age with the excep-
tion of a negative association between AEA plasma and 
age in men (r = − 0.522, p = 0.032) independently of BMI, 
was found.
Table 1  Characteristics of the study participants with ileostomy
BMI Body mass index, PA physical activity, LA linoleic acid, ALA alpha-linolenic acid, AA arachidonic acid, EPA eicosapentaenoic acid, DPA 
docosapentaenoic acid, DHA docosahexaenoic acid, PUFA polyunsaturated fatty acids, CRP C-reactive protein
Data are expressed as means ± SEM. Medications are expressed as means (range) of dosages (mg/kg body weight/day) taken by total (n) sub-
jects; n women (W), n men (M)
a p < 0.05 in bold indicates significant difference between women and men, by Student’s t test or Mann-Whithney test depending on data normal 
distribution
b Self-reported data collected using a validated physical activity (PA) questionnaire [39]
c Total PUFA: sum of LA, ALA, AA, EPA, DPA, DHA
d n-6:n-3 ratio: (sum of LA and AA)/(sum of ALA, EPA, DPA and DHA)
All (n = 35) Women (n = 18) Men (n = 17) p  valuea
General characteristics and anthropometry
 Age (years) 51.1 ± 2.4 50.8 ± 3.8 51.4 ± 3.0 0.898
 Height (cm) 168.1 ± 1.3 162.7 ± 1.2 173.9 ± 1.4  < 0.001
 Weight (kg) 76.4 ± 3.1 68.3 ± 3.1 85.0 ± 4.9 0.006
 BMI (kg/m2) 26.9 ± 0.9 25.9 ± 1.2 28.0 ± 1.5 0.266
 Ileal fluids pH 6.1 ± 0.1 6.1 ± 0.1 6.1 ± 0.1 0.908
 Ileal fluids net weight (g) 234.6 ± 15.9 229.1 ± 15.4 240.5 ± 28.9 0.732
 PA energy expenditure (MET h/day)b 21.6 ± 3.0 16.2 ± 1.8 27.3 ± 5.8 0.087
Serum lipids
 Triglycerides (mmol/L) 0.92 ± 0.08 0.92 ± 0.12 0.92 ± 0.12 0.840
 Total cholesterol (TC, mmol/L) 3.52 ± 0.14 3.69 ± 0.19 3.33 ± 0.19 0.190
  LDL-cholesterol (mmol/L) 1.94 ± 0.12 2.02 ± 0.17 1.86 ± 0.16 0.509
  HDL-cholesterol (mmol/L) 1.16 ± 0.05 1.26 ± 0.04 1.05 ± 0.08 0.030
 LA (mg/mL) 1.10 ± 0.04 1.16 ± 0.05 1.04 ± 0.05 0.131
 ALA (mg/mL) 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.245
 AA (mg/mL) 0.28 ± 0.02 0.28 ± 0.02 0.27 ± 0.02 0.815
 EPA (mg/mL) 0.01 ± 0.00 0.02 ± 0.00 0.01 ± 0.00 0.226
 DPA (mg/mL) 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.918
 DHA (mg/mL) 0.03 ± 0.00 0.04 ± 0.01 0.02 ± 0.00 0.093
 Total PUFA (mg/mL)c 1.45 ± 0.05 1.52 ± 0.07 1.37 ± 0.07 0.144
 n-6:n-3  ratiod 28.67 ± 3.15 28.41 ± 4.62 28.93 ± 4.40 0.451
Inflammatory status
 CRP (mg/L) 3.30 ± 0.66 3.71 ± 1.18 2.87 ± 0.57 0.719
Medications (mg/kg b.w./day)
 Antihistamine (n = 5; 2W, 3M) 0.28 (0.15–0.42) 0.29 (0.15–0.42) 0.27 (0.21–0.35)
 Antidiarrheal (n = 5; 2W, 3M) 0.22 (0.08–0.39) 0.17 (0.16–0.17) 0.25 (0.08–0.39)
 Antihypertensive (n = 4; 1W, 3M) 1.42 (0.06–3.10) 1.65 1.34 (0.06–3.10)
 Antacids (n = 7; 3W, 4M) 0.43 (0.19–0.86) 0.51 (0.42–0.66) 0.38 (0.19–0.86)
 Antidepressant (n = 5; 2W, 3M) 0.49 (0.24–1.07) 0.39 (0.32–0.47) 0.56 (0.24–1.07)
 Cholesterol lowering (n = 6; 2W, 4M) 0.49 (0.33–0.66) 0.62 (0.58–0.66) 0.42 (0.33–0.51)
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Diet and correlations with plasma and ileal fluids 
of ECs, NAEs and NAPEs
Table 2 shows daily energy value and macronutrient com-
position of diets self-reported by the participants. Women 
reported significantly lower energy, carbohydrate, protein 
and fat intakes than men but a similar repartition of energy 
among macronutrients; only the % energy from dietary fiber 
was higher in women than in men. Self-reported dietary 
intakes and plasma concentrations of PUFAs were simi-
lar between sexes (Table 1). Overall dietary intake of n-3 
PUFAs was lower (1.2 ± 0.21 g) compared to the intake of 
n-6 PUFAs (5.8 ± 0.68 g), reflecting a limited consumption 
of foods like oily fish in the cohort with only 6 out of 34 
Fig. 2  N-acylethanolamines (a) and N-acylphosphatidylethanola-
mines (b) concentrations in ileal fluids from the overall population 
(n = 35), LEA (c) and OEA (d) concentrations in ileal fluids from 
men (M, empty dots; n = 17) and women (W, solid dots; n = 18) and 
PEA (e) concentrations in ileal fluids from participants with normal-
weight (NW; n = 11), overweight (OW; n = 12) and obesity. Different 
letters on the box plots indicate p value < 0.05 by One-way ANOVA 
and Bonferroni adjustement for multiple comparisons or by Student’s 
t test. Total NAEs include the sum of LEA, OEA, PEA and SEA. 
LEA Linoylethanolamide, OEA oleoylethanolamide, PEA palmitoy-
lethanolamide, SEA stearoylethanolamide, NAEs N-acylethanolam-
mines, NAPEs N-acylphosphatidylethanolamines. The box plots show 
the data distribution based on first quartile, median and third quartile
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participants reporting intake (group average 55 ± 60 g/day) 
and only two consumed canned oily fish (group average 
23.1 ± 9.7 g/day). Whereas foods rich in n-6 PUFAs, such as 
chicken (22/34 participants, group average 65.7 ± 61.2 g/day) 
and eggs (20/34 participants, group average 21.8 g ± 12.1 g/
day), were consumed in greater quantities and by more par-
ticipants. Only nine participants consumed nuts and seed 
(group average 17.6 ± 16.0 g/day) a rich source of MUFAs. 
The relative amounts (g) of self-reported food consumption 
for all participants in the study are shown in Supplementary 
Table 3.
A logarithmic correlation analysis between ileal and 
plasma concentrations of ECs, NAEs and NAPEs with 
habitual self-reported energy and nutrient intakes, was per-
formed. Results showed that ileal concentrations of LEA 
positively correlated with individual energy intake whereas 
plasma concentrations of LEA, OEA and AEA inversely 
correlated with it. Moreover, we found that ileal concentra-
tions of LEA and OEA positively correlated with fat intake 
whereas plasma concentrations of LEA, OEA, and AEA 
were negatively correlated. Specifically, plasma concentra-
tions of LEA and AEA negatively correlated with saturated 
fat intake; PEA negatively correlated with n6, n3 series and 
PUFA intake; OEA negatively correlated with PUFA and 
AEA with MUFA intake. Moreover ileal LEA and OEA 
were positively associated with saturated fat and trans fat 
intake. All the correlations found are detailed in Supple-
mentary Table 4.
Correlations between serum PUFA and ECs, NAEs 
and NAPEs
Plasma LEA and 2-AG concentrations were negatively 
associated with AA while SEA was positively associated 
Fig. 3  Plasma Endocannabinoids (a), N-acylethanolammines (b) and 
N-acylphosphatidylethanolamines (c) concentrations in the over-
all population (n = 35) and N-acylphosphatidylethanolamines (d) 
plasma concentrations from participants with normalweight (NW; 
n = 11), overweight (OW; n = 12) and obesity (OB, n = 11). Different 
letters on the box plots indicate p value < 0.05 by One-way ANOVA 
and Bonferroni adjustement for multiple comparisons. Total ECs 
include the sum of 2-AG and AEA; total NAEs include the sum of 
LEA, OEA, PEA and SEA. 2-AG 2-Arachidonoylglicerol, AEA 
arachidonoylethanolamide, ECs endocannabinoids, LEA linoyle-
thanolamide, OEA oleoylethanolamide, PEA palmitoylethanolamide, 
SEA stearoylethanolamide, NAEs N-acylethanolammines, NAPEs 
N-acylphosphatidylethanolamines. The box plots show the data distri-
bution based on first quartile, median and third quartile
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with DHA and n3 fatty acids. Concentrations of NAPEs 
in ileal fluids were positively associated with plasma EPA 
and DPA. All the correlations found are shown in Sup-
plementary Table 5.
Discussion
The implications of the endocannabinoid system and its 
role in human health have become an area of increasing 
Fig. 4  Correlation between individual plasma concentrations of PEA 
(a), BMI (b) and individual serum CRP. Men (M, n = 17) are indi-
cated with empty dots and women (W, n = 18) with solid dots. R and 
p value are assessed by Pearson correlation on ln transformed varia-
bles. PEA palmitoylethanolamide, CRP C-reactive protein, BMI Body 
Mass Index
Table 2  Nutritional composition 
of habitual diets of all the study 
participants and by sexes
Data are expressed as mean ± SEM, obtained from self-reported 4-day food diaries
SFA saturated fatty acids, MUFA monounsaturated fatty acids, PUFA polyunsaturated fatty acids, n-3 FA 
omega-3 fatty acids, n-6 FA omega-6 fatty acids
a p < 0.05 in bold indicates significant difference between women and men, by Student’s t test
All (n = 34) Women (n = 18) Men (n = 16) p  valuea
Energy (kJ kcal) 8292.8 ± 364.2 7176.5 ± 393.7 9548.7 ± 473.4  < 0.001
1982.0 ± 87.1 1715.2 ± 94.1 2282.2 ± 113.1
Carbohydrates (g) 221.9 ± 9.3 195.8 ± 9.9 251.3 ± 13.0 0.002
% Energy 45.3 ± 1.0 46.2 ± 1.4 44.3 ± 1.4 0.334
Dietary fiber (g) 17.8 ± 0.8 17.7 ± 1.2 17.9 ± 1.0 0.914
% Energy 1.9 ± 0.1 2.1 ± 0.2 1.6 ± 0.1 0.006
Proteins (g) 85.5 ± 4.6 73.0 ± 5.4 99.5 ± 6.1 0.002
% Energy 17.4 ± 0.7 17.0 ± 0.8 17.9 ± 1.2 0.519
Fats (g) 79.7 ± 5.0 67.2 ± 5.4 93.7 ± 7.4 0.006
% Energy 35.4 ± 1.1 34.7 ± 1.6 36.2 ± 1.4 0.476
SFA (g) 30.2 ± 2.5 24.6 ± 2.7 36.5 ± 4.0 0.011
MUFA (g) 29.0 ± 1.9 23.9 ± 2.0 34.8 ± 2.6 0.002
PUFA (g) 12.4 ± 0.9 11.0 ± 1.1 13.9 ± 1.5 0.107
Total n-3 FA (g) 1.2 ± 0.2 1.0 ± 0.2 1.4 ± 0.4 0.325
Total n-6 FA (g) 5.8 ± 0.7 6.3 ± 1.0 5.3 ± 1.0 0.458
Trans fats (g) 1.1 ± 0.1 1.0 ± 0.2 1.1 ± 0.1 0.584
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interest over the last decade [5]. To date, only a limited 
number of studies have actually measured ECs, NAEs and 
NAPEs in human biological fluids with circulating ECs 
reported in the range 0.2–9.4 ng/mL (12 studies), NAEs 
ranging 0.5–64.6 ng/mL (10 studies), and NAPEs rang-
ing 120.7–800.0 ng/mL (2 studies) [29, 33, 34, 48–50]. 
While ECs are acknowledged key mediators in the inter-
play between gut, microbiota and metabolic health, to the 
best of our knowledge, their levels and those of NAEs and 
NAPEs in the gastro-intestinal tract are largely unknown 
with only one recent human study reporting fecal con-
centration for single NAPE [51]. In this study, for the 
first time, the concentrations of ECs, NAEs and NAPEs 
within the GIT are measured, via ileal fluid, revealing the 
amount of the compounds that would be colon-available 
upon leaving the small intestine. We determined that ileal 
NAEs and particularly OEA (383.72 ± 88.78 ng/mL), LEA 
(2360.10 ± 454.74 ng/mL) and PEA (377.72 ± 26.08 ng/
mL) were on average 1.5–13 times higher than that 
required to elicit a physiological response through the 
intestinal receptors. Indeed, the agonist activity (EC50) 
of such compounds on GPR119 ranges from 65 ng/mL to 
1.0 µg/mL for OEA, 180 ng/mL for LEA and 250 ng/mL 
for PEA [52, 53]; OEA also displayed agonist activity on 
PPAR-α with an EC50 of 39 ng/mL [15].
In the present study, ileal samples were collected from 
stoma bags filled during the overnight fasting period and 
consequently may contain some food residues from the 
last meal consumed by the participants prior to the fast-
ing period. Therefore, food eaten in that meal might have 
directly influenced the lipid type and amount in ileal fluids 
whose composition is more susceptible to individual diges-
tion rate than fasting plasma samples. This may explain the 
differences in the lipids’ profiles between ileal fluids and 
plasma and why, for example, LEA is the most abundant 
NAE in the ileal samples while it is the less abundant in 
plasma. Indeed, we hypothesize that dietary NAEs and 
NAPEs [35] may result from digestive processes in the 
proximal GIT following mastication [36, 37], being into 
the alimentary canal postprandially at concentrations even 
higher than those found in this study. Such an effect could 
trigger GLP-1 secretion by enterocytes through activation 
of intestinal GPR119, thus contributing to the homeostatic 
regulation of food intake, which is consistent with the find-
ings from Chen and co-workers [54] showing that feeding 
mice with NAPE-synthesizing bacteria increased delivery 
of NAEs/NAPEs in the intestinal lumen and significantly 
reduced food intake and adiposity induced by a high-fat 
diet. In the case of intestinal NAPEs, their activity neces-
sitates conversion into NAEs through the action of intes-
tinal NAPE-hydrolyzing phospholipase D [55]. NAEs and 
NAPEs, therefore, appear to be more effective in elicit-
ing a leptogenic effect from the intestinal lumen than in 
other tissues. Consequently, more robustly designed stud-
ies are needed to elucidate the physiological relevance 
of diet-induced increases in intestinal NAEs and NAPEs 
postprandially.
It should be noted, that correlations between ileal and 
plasma LEA and OEA with energy and fat intakes concomi-
tant with the sex differences suggested that an individual’s 
diet may influence NAEs intestinal and plasma concentra-
tions. Dosoky and co-workers reported that fecal concen-
trations of NAPEs (NAEs precursors) in mice fed with a 
plant-based diet were significantly higher than in mice fed a 
lard-based high-fat diet [56], which is in line with our obser-
vations that NAPEs are more abundant in plant compared to 
animal foods [35].
In agreement with Balvers and co-workers, we found that 
total plasmatic NAPEs were about 13- to 32-fold higher 
than NAEs [57] and were more abundant in OB than NW 
and OW. Plasma concentrations of ECs and NAEs in the 
ileostomy cohort (average BMI 26.9 ± 0.9) were in the same 
order of magnitude to those previously measured in over-
weight and obese subjects with intact GI tracts [19, 28, 29, 
32]. In contrast, we did not find any association between 
2-AG and AEA with BMI and this is consistent with the 
reported heterogeneity of observations in the literature, 
whereby plasma 2-AG has been positively correlated with 
BMI [25, 26] and yet no in other studies [19, 58]. Similarly, 
AEA plasma concentrations were elevated in obese subjects 
compared to normal weight subjects [19, 27, 32] yet other 
studies report no association with BMI [25, 26].
Other characteristics than BMI which are often disre-
garded in the populations studied, such as the body composi-
tion, the number of women in menopause or the use of drugs 
or dietary supplements, may be responsible of the different 
findings between literature studies.
We found sex correlations between the plasma concen-
trations of AEA, OEA and PEA with individual age and 
only our observations in women were in agreement with 
Fanelli et al. [32]. However, serum-free fatty acids were not 
positively associated with NAEs and AEA in contrast to a 
previous study in healthy women [59]. The heterogeneity 
observed is likely due in part to the different age and BMI 
ranges of the study populations used.
Few studies currently in the literature, reported on 
whether drugs affected plasma ECs and NAEs other than 
in relation to treating depression, whereby circulating 
2-AG was halved while AEA was unchanged in patients 
with major depression compared to healthy subjects [60, 
61] and antidepressant use did not change plasma EC nor 
NAE concentrations [61]. In our study, AEA plasma con-
centrations were about 2- to 4-fold higher than those of 
depressed patients [60, 61], whereas 2-AG plasma con-
centrations were consistent [61] or ~ 15-fold lower than 
patients with depression [60].
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Inflammatory status (CRP) was positively correlated 
with the nutritional status as assessed by BMI and was 
consistent with previous studies [62]. On the other hand, 
the positive association we found between plasma concen-
trations of PEA and CRP, independently of BMI, was in 
agreement with animal and human studies showing that 
circulating and tissue PEA concentrations increased in 
subjects suffering from inflammatory diseases, such as 
neuropathic and inflammatory pain or ulcerative colitis 
[63]. Furthermore, a recent study reported elevated con-
centrations of a NAPE, namely 18:1/16:1/18:0, in the fae-
ces of patients suffering from ulcerative colitis in compari-
son to healthy controls [51].
This study has some limitations. Firstly, the habitual 
diet and physical activity energy expenditure were esti-
mated by self-reported data from participants using previ-
ously validated survey instruments, which is not as reliable 
as direct observations. Second, since we did not measure 
total energy expenditure, we could not estimate if par-
ticipants were in energy balance. If subjects were not in 
energy balance, this might alter the implications of our 
observations. Finally, the possible presence of residues of 
the dinner in the ileal fluids makes any attempt to identify 
the relationships between ileal and plasma content chal-
lenging in this study.
In conclusion, we assessed, for the first time, the con-
centrations of ECs, NAEs and NAPEs present in ileal flu-
ids from participants with ileostomy and, thus, established 
the amounts likely to be entering the colon in individuals 
with an intact GIT. Men had higher ileal concentrations 
of OEA and LEA than women which positively correlated 
with the self-reported dietary higher energy and fat intake. 
An ongoing intervention study will address whether the 
dietary intakes of NAPEs and NAEs affect the concentra-
tions of NAEs in the intestinal lumen postprandially and if 
they contribute to the homeostatic control of food intake.
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